Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo Starts Search For Campanelli’s Successor

Endo Chief Will Move To Become Chairman

Executive Summary

With Endo’s CEO Paul Campanelli intending to step down for personal reasons, the US brands and generics player’s board has started to look for external and internal candidates to take over.

You may also be interested in...



Who’s Hired? AAM Makes Three Key Appointments

The US Association for Accessible Medicines hires for three key leadership roles, while Australia’s Generic and Biosimilar Medicines Association has named Fresenius Kabi’s director in Australia as its newest board member. Coherus’ vice president of market access and government affairs, Thomas Nusbickel, joins CorMedix as chief commercial officer, while other major firms make board changes.

Endo's New Chief Has Challenges Ahead

Set to take charge of the company on 6 March, Endo's incoming chief Blaise Coleman must tackle Endo's multi-billion-dollar debt and steer the firm back to profitability after several years of significant losses.

Who’s Hired? Endo Names New CEO

Endo has named a new CEO and CFO, while Mylan and Pfizer’s Viatris has found its CFO and announced its full roster of board members. Meanwhile, Assogenerici names the leaders of its value added medicines sector group, law firm Fish & Richardson gets a new CEO and France appoints a new health minister.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel